TriSalus Life Sciences announced the closing of a private placement, raising approximately $22.0 million in gross proceeds. This capital infusion is intended to strengthen the company's balance sheet and fund planned investments in commercial expansion and new applications for its Pressure-Enabled Drug Delivery (PEDD) technology.
Alongside the financing, the company also reported preliminary unaudited financial results for the first quarter of 2025. Preliminary Q1 2025 revenue was $9.2 million, representing a 42% increase compared to Q1 2024 and an 11% sequential gain over Q4 2024.
This significant equity raise provides TriSalus with additional liquidity to support its growth-oriented strategy. The strong preliminary revenue figures indicate continued commercial momentum for the TriNav system.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.